MedTrace Logo

Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer

NCT04970498 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-07-21

No results posted yet for this study

Summary

Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group. The differences of magnetic resonance parameters between the groups were compared. The risk identification model of acute and chronic myelosuppression after neoadjuvant chemoradiotherapy was established by clinical risk factors and quantitative parameters of magnetic resonance imaging, and the prediction efficiency of the model was evaluated.

Conditions

  • Rectal Cancer Stage II
  • Rectal Cancer Stage III

Interventions

DIAGNOSTIC_TEST

MRI

MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed

DIAGNOSTIC_TEST

blood routine test

The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Ning Lang, Professor · Peking University Third Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-08-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970498 on ClinicalTrials.gov